Sustained Remission in Rheumatoid Arthritis: Time to Withdraw Treatment?
Can M SungurPublished in: ACR open rheumatology (2021)
With increasing numbers of patients with rheumatoid arthritis achieving sustained remission, medication withdrawal is an important consideration to reduce polypharmacy and associated adverse events. An article from the journal Arthritis & Rheumatology (1) explores the treatment withdrawal options for patients on etanercept and methotrexate combination therapies and suggests methotrexate withdrawal has the least impact on disease worsening. There are limitations in the study, including the use of only one disease activity score and no assessment of radiographic progression, but, overall, the article provides a good framework for future studies on treatment withdrawal options and the possibility of medication reduction for patients.
Keyphrases
- rheumatoid arthritis
- disease activity
- end stage renal disease
- ankylosing spondylitis
- systemic lupus erythematosus
- rheumatoid arthritis patients
- newly diagnosed
- ejection fraction
- chronic kidney disease
- juvenile idiopathic arthritis
- healthcare
- prognostic factors
- peritoneal dialysis
- emergency department
- high dose
- interstitial lung disease
- patient reported outcomes
- current status
- idiopathic pulmonary fibrosis
- electronic health record